Integra LifeSciences, a dominant force in neurosurgery with a leading Codman Specialty Surgical segment, showcased modest revenue growth yet faced substantial operating losses in fiscal 2025. Despite launching advanced products such as the Aurora Surgiscope and advancing clinical evidence through registries, the company grappled with FDA warning letters and manufacturing compliance hurdles which challenged its operational performance. Liquidity remains adequate with covenant relief in place, but increasing leverage and curtailed share repurchases highlight cautious capital allocation. Monitoring regulatory progress, registry outcomes, and geographic expansions will be key to understanding Integra’s near-term trajectory.